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Amyotrophic	lateral	sclerosis	(ALS)	and	frontotemporal	lobar	degeneration	(FTLD)	are	characterized	by	cyto-
plasmic	protein	aggregates	in	the	brain	and	spinal	cord	that	include	TAR-DNA	binding	protein	43	(TDP-43).	
TDP-43	is	normally	localized	in	the	nucleus	with	roles	in	the	regulation	of	gene	expression,	and	pathological	
cytoplasmic	aggregates	are	associated	with	depletion	of	nuclear	protein.	Here,	we	generated	transgenic	mice	
expressing	human	TDP-43	with	a	defective	nuclear	localization	signal	in	the	forebrain	(hTDP-43-ΔNLS),	and	
compared	them	with	mice	expressing	WT	hTDP-43	(hTDP-43-WT)	to	determine	the	effects	of	mislocalized	
cytoplasmic	TDP-43	on	neuronal	viability.	Expression	of	either	hTDP-43-ΔNLS	or	hTDP-43-WT	led	to	neuron	
loss	in	selectively	vulnerable	forebrain	regions,	corticospinal	tract	degeneration,	and	motor	spasticity	recapit-
ulating	key	aspects	of	FTLD	and	primary	lateral	sclerosis.	Only	rare	cytoplasmic	phosphorylated	and	ubiqui-
tinated	TDP-43	inclusions	were	seen	in	hTDP-43-ΔNLS	mice,	suggesting	that	cytoplasmic	inclusions	were	not	
required	to	induce	neuronal	death.	Instead,	neurodegeneration	in	hTDP-43	and	hTDP-43-ΔNLS–expressing	
neurons	was	accompanied	by	a	dramatic	downregulation	of	the	endogenous	mouse	TDP-43.	Moreover,	mice	
expressing	hTDP-43-ΔNLS	exhibited	profound	changes	in	gene	expression	in	cortical	neurons.	Our	data	sug-
gest	that	perturbation	of	endogenous	nuclear	TDP-43	results	in	loss	of	normal	TDP-43	function(s)	and	gene	
regulatory	pathways,	culminating	in	degeneration	of	selectively	vulnerable	affected	neurons.
Introduction
Frontotemporal lobar degeneration (FTLD) and amyotrophic 
lateral sclerosis (ALS) are characterized by the presence of ubiqui-
tin-positive inclusions (1). These inclusions are found in the brain 
and spinal cord of ALS patients as well as in patients with a major 
subtype of FTLD designated FTLD-TDP because these inclusions 
were shown to be comprised of the TAR-DNA binding protein 43 
(TDP-43) (2). Since (a) cognitive abnormalities or dementia con-
sistent with FTLD are increasingly recognized in ALS patients, (b) 
some FTLD patients develop MND, and (c) cytoplasmic TDP-43 
aggregates are found in the brain and spinal cord of both ALS and 
FTLD-TDP patients, TDP-43 pathology appears to define a single 
neurodegenerative disorder (TDP-43 proteinopathy) with a spec-
trum of clinical manifestations (3–5). The importance of TDP-43 
in the pathogenesis of these diseases is supported by the presence 
of autosomal dominant mutations in the TARDBP gene associated 
with ALS and FTLD (6).
Human TDP-43 (hTDP-43) is a highly conserved and ubiqui-
tously expressed 414–amino acid nuclear protein that binds to 
both DNA and RNA (7, 8). TDP-43 is implicated in repression of 
gene transcription, regulation of exon splicing, and nuclear body 
functions (for a summary see recent reviews, refs. 4 and 6). Patho-
logical TDP-43 can be abnormally cleaved, phosphorylated, and 
ubiquitinated, and most TDP-43 aggregates are mislocalized out-
side the nucleus within the cytoplasm or neurites (2). Interestingly, 
cells that develop TDP-43 accumulations show a dramatic deple-
tion of normal nuclear TDP-43. Thus, both gain and loss of func-
tions are potential disease mechanisms, either due to the loss of 
normal nuclear TDP-43 expression, cytoplasmic mislocalization, 
or cytoplasmic aggregation (2, 9, 10).
To mimic this nuclear clearance and to model the formation of 
TDP-43 cytoplasmic aggregates, we have shown that expression 
of hTDP-43 with mutated nuclear localization signals (hTDP-43-
ΔNLS) in cultured cells reduces endogenous nuclear TDP-43 and 
accumulates as cytoplasmic aggregates (11). In vivo mouse models 
with TDP-43 knockout or overexpression have also been reported. 
Tardbp-null mice are embryonic lethal (12–15), and conditional 
Tardbp null mice exhibit rapid postnatal death associated with 
aberrations in fat metabolism (15). Tg mice with overexpression of 
human or mouse TDP-43-WT as well as mice expressing TDP-43 
harboring disease-associated mutations have been reported to show 
TDP-43 pathologies associated with motor neuron degeneration 
reminiscent of ALS or FTLD-TDP (16–20). However, the effects of 
cytoplasmic TDP-43 expression on the formation of cytoplasmic 
aggregates, neurotoxicity, and normal nuclear TDP-43 protein on 
initiating neurodegeneration have not been addressed in vivo.
Here, we generated Tg mice with inducible forebrain overex-
pression of hTDP-43-ΔNLS using the Camk2a tetracycline trans-
activator (Camk2a tetO) to specifically model cytoplasmic mis-
localization of TDP-43 and interrogate the consequences of this 
abnormal distribution of TDP-43 in the presence or absence of 
TDP-43 aggregates. We found profound neuron loss in specific 
regions, in particular, cortex (including motor cortex) and hippo-
campus, with corticospinal tract (CST) degeneration and a spastic 
motoric phenotype, all of which recapitulate key aspects of FTLD 
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and primary lateral sclerosis (PLS). However, only small numbers 
of phosphorylated and ubiquitinated cytoplasmic hTDP-43 aggre-
gates are found in hTDP-43-ΔNLS Tg mice, and they do not corre-
late with the observed profound neurotoxicity. Instead, a dramatic 
loss of endogenous nuclear mouse TDP-43 (mTDP-43) was the 
only correlate to neurodegeneration in hTDP-43-ΔNLS–expressing 
mice. Significantly, this was associated with a strikingly abnormal 
and selective upregulation of chromatin assembly genes in hTDP-
43-ΔNLS Tg mice. We conclude that endogenous nuclear TDP-43 is 
highly regulated and that perturbation of nuclear TDP-43 is associ-
ated with profound alterations in gene expression and cell death.
Results
Generation of Tg mice overexpressing hTDP-43-WT and hTDP-43-ΔNLS 
proteins. To create conditional mouse models of TDP-43 proteinop-
athies, we generated Tg mice expressing hTDP-43-ΔNLS and its 
control counterpart hTDP-43-WT using CaMK2α promoter ele-
ments to drive tet-off tTA (Camk2a-tTA) and a tetracycline respon-
sive promoter to drive hTDP-43 expression (tetO-hTDP-43; Fig-
ure 1A) (21–23). Bigenic mice (Camk2a-tTA x tetO-hTDP-43) were 
maintained on Doxycycline (Dox) to inhibit transgene expression 
until 28 days of age when they were switched to a Dox-free diet and 
sacrificed at the designated time points off Dox (Figure 1B).
We identified 2 lines overexpressing hTDP-43-ΔNLS (big-
enic mice designated tTA/TDP-ΔNLS) and 4 lines overexpress-
ing hTDP-43-WT (bigenic mice designated tTA/TDP-WT) that 
expressed differing levels of TDP-43, ranging from 8- to 9-fold 
over endogenous mTDP-43 for tTA/TDP-ΔNLS mice and from 
0.4- to 1.7-fold over endogenous mTDP-43 for tTA/TDP-WT mice 
(Figure 1C). We selected 1 line of tTA/TDP-ΔNLS (ΔNLS4) for 
Figure 1
Generation and biochemical characterization of inducible TDP-43 Tg mice. (A) Generation of conditional Tg mice. Camk2a-tTA mice were 
crossed with tetO-TDP-WT or tetO-TDP-ΔNLS mice. In bigenic mice, Dox inhibits tTA binding to the tetracycline-responsive promoter element 
(tetO), repressing hTDP-43 expression. (B) Dox was removed at weaning (P28) followed by analysis at the indicated time points. (C) Expression 
of hTDP-43 in Tg mice. Immunoblot of hTDP-43 or total TDP-43 (h+mTDP-43) in cortical RIPA extracts (1 month off Dox) of nTg, tTA, tTA/TDP-
WT (WT4, WT8, WT5 and WT12), and tTA/TDP-ΔNLS mice (ΔNLS4 and ΔNLS19) showed variable expression of hTDP-43. GAPDH is a loading 
control. Fold expression relative to nTg and tTA control mice is shown, as described in Methods. (D) Regional expression of hTDP-43. RIPA 
extracts from different brain regions of tTA/TDP-WT or tTA/TDP-ΔNLS mice (1 month off Dox) were immunoblotted for hTDP-43, h+m TDP-43, 
and GAPDH. Ctx, cerebral cortex; Hp, hippocampus; OB, olfactory bulb; Cb, cerebellum; Rest, brain stem plus subcortical gray regions; SC, 
spinal cord. (E) Low levels of insoluble hTDP-43. Sequential cortical extracts from tTA/TDP-WT and tTA/TDP-ΔNLS mice of increasing time off 
Dox were immunoblotted for hTDP-43 showing low levels of TDP-43 in urea fractions. Urea lysates were loaded at 4× relative to RIPA lysates 
so that the low level of insoluble TDP-43 could be seen. R, RIPA; U, urea. n = at least 3 animals per group analyzed in C–E.
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in-depth analysis with the tTA/TDP-WT12 line as a control line, 
although the other Tg lines also were studied to ensure consistency 
of the relationship between phenotype and expression levels. Sin-
gle Tg mice (tetO-TDP-ΔNLS or tetO-TDP-WT) showed little to no 
hTDP-43 expression indicative of very low tetO activity or “leaki-
ness” (data not shown).
Mice showed neuronal expression predominantly, albeit not 
exclusively, in forebrain structures, consistent with the properties 
of the Camk2a promoter (21, 22). To demonstrate the regional dif-
ferences in TDP-43 expression, protein lysates were analyzed using 
antibodies specific for hTDP-43 and antibodies recognizing both 
hTDP-43 and endogenous mTDP-43 (h+mTDP-43). High TDP-43 
expression was found in cortex, hippocampus, and olfactory bulb, 
while cerebellum, subcortical regions/brain stem, and spinal cord 
displayed no or barely detectable hTDP-43 (Figure 1D). Sequen-
tial extraction using RIPA and urea buffers of cortex from bigenic 
WT12 and ΔNLS4 Tg mice showed the majority of hTDP-43 and 
mTDP-43 protein was recovered in the RIPA fraction (Figure 1E). 
However, low levels of TDP-43 (<10%) were detected in the urea frac-
tion (Figure 1E), and C-terminal TDP-43 fragments (CTFs) were 
not found in any line at any of the time points examined (Supple-
mental Figure 1; supplemental material available online with this 
article; doi:10.1172/JCI44867DS1). Importantly, all tTA/TDP-WT 
and tTA/TDP-ΔNLS lines showed nearly complete suppression of 
transgene under constant Dox treatment (data not shown).
tTA/TDP-WT mice show progressive neurodegeneration. Overexpres-
sion of TDP-43-WT protein is known to be neurotoxic (16–20). To 
determine whether hTDP-43-WT exhibited similar neurotoxicity 
in our conditional WT12 line, a time course of neuron loss and the 
distribution of hTDP-43-WT protein was assessed by histological 
Figure 2
Neuron loss and cerebral atrophy in tTA/TDP-WT mice. (A–L) Expression of hTDP-43 and time-dependent cell loss in tTA/TDP-WT12 mice. 
(A–D) H&E sections of nTg (A) and tTA/TDP-WT12 (B–D) brain revealed time-dependent hippocampal neuron loss in bigenic mice. Note the 
loss of DG neurons as indicated by arrowheads. (E–L) Nuclear expression of hTDP-43. IHC for hTDP-43 (E–H) and h+mTDP-43 (I–L) showed 
mosaic nuclear expression of hTDP-43 in tTA/TDP-WT12 and a severe thinning of the DG cell layer after 3 to 6 months off Dox. Insets in E–L 
display higher magnification of DG neurons. Scale bars: 500 μm (A–D); 200 μm (E–L). (M) Loss of DG neurons in tTA/TDP-WT12 mice. Quan-
tification of DG neurons shows progressive neuron loss in tTA/TDP-WT12 mice. (N) Time-dependent brain atrophy in tTA/TDP-WT12 mice. 
There was a progressive reduction in total brain weight in tTA/TDP-WT12 mice. Data in M and N represent mean ± SEM (n = 3–4 per group). 
*Significantly different from nTg (P < 0.001); ###significantly different from 1 month off Dox (P < 0.001); #significantly different from 1 month off 
Dox (P < 0.05); ‡significantly different from 3 months off Dox (P < 0.05).
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and immunohistochemical (IHC) analyses of these mice (Figure 2). 
Although nTg and single Tg littermates never showed signs of 
neurodegeneration, H&E-stained sections of tTA/TDP-WT brain 
showed time-dependent neuron loss in the hippocampal dentate 
gyrus (DG) and neocortex beginning at about 1 month, and this 
became progressively more severe from 3 to 6 months (Figure 2, A 
and D). Quantification of DG neuron loss showed approximately 
20% loss of DG neurons at 1 month and approximately 75% loss by 
3 months after Dox removal, which was paralleled by progressive 
brain atrophy as assessed by histology and total brain weight (Fig-
ure 2, M and N). Astrocytic and microglial activation were seen in 
cortex and hippocampus by IHC with antibodies to glial fibrillary 
acidic protein (GFAP) and Iba-1 as early as 1 month off Dox (Sup-
plemental Figure 2A and data not shown). Importantly, WT8 mice 
(low expressors) showed no detectable neuron loss at 3–4 months 
in contrast with WT4 mice (high expressors), which showed DG 
neurodegeneration as early as 7–10 days after Dox removal (data 
not shown). This suggests that there may be a threshold effect, 
with neurodegeneration occurring as a function of higher levels of 
exogenous hTDP-43 expression.
IHC for hTDP-43-WT in line WT12 revealed predominantly 
nuclear localization (Figure 2, F–H), with a mosaic pattern rang-
Figure 3
Cytoplasmic hTDP-43 expression and progressive neuronal loss in tTA/TDP-ΔNLS mice. (A–D) Progressive neuron loss in tTA/TDP-ΔNLS4 
mice. Hippocampal H&E sections of nTg (A) and tTA/TDP-ΔNLS (B) mice show a progressive DG neuron loss evident from 1 month off Dox 
(arrowhead highlights DG degeneration). (E–J) Cytoplasmic TDP-43 expression in tTA/TDP-ΔNLS hippocampus. IHC for hTDP-43 (E–G) or h+m 
TDP-43 (H–J) was performed on hippocampal sections from bigenic mice 1 week off Dox showing predominantly cytoplasmic expression of TDP-
43. Insets show nTg mice with no hTDP-43 expression and nuclear h+mTDP-43 expression. Scale bars: 500 μm; (A–D, E and H); 200 μm (F, 
G, I, and J). (K) Loss of DG neurons in tTA/TDP-ΔNLS4 mice. Quantification of DG neurons shows progressive neuronal loss in tTA/TDP-ΔNLS 
mice. Data shown represent mean ± SEM (n = 3–4 per group). *Significantly different from nTg (P < 0.001). (L) Immunoblot analysis of enriched 
cytoplasmic (C) and nuclear (N) fractions isolated from cortical extracts of monogenic tTA and 2-month-old bigenic tTA/TDP-ΔNLS mice 10 days 
off Dox showing the presence of hTDP-43 in both fractions in tTA/TDP-ΔNLS. Note endogenous mTDP-43 is predominately nuclear. Nuclear 
hnRNP A2/B1 and cytoplasmic HSP90 indicated that the fractions are well separated.
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ing from neurons showing strong staining to those with negligible 
staining. This variability was corroborated with an antibody that 
detects both hTDP-43 and mTDP-43 (h+mTDP-43), as seen by 
comparing nTg in Figure 2I with hTDP-43-WT in Figure 2, J–L. 
The number of hTDP-43–expressing neocortical neurons appeared 
to increase with time off Dox so that approximately 50% of neurons 
expressed hTDP-43 by 3 months (see Supplemental Figure 7A). 
Notably, in all of the tTA/TDP-WT lines examined, only extremely 
rare TDP-43 inclusions were identified in cortical and hippocampal 
neurons (<0.1% of neurons; see Supplemental Figure 2B) using 
antibodies that recognize phosphorylated TDP-43 at Ser409 and 
410 (p409/410) or ubiquitin. TDP-43 inclusions were not seen in 
nTg and single tetO-TDP-WT mice. Thus, hTDP-43-WT expression 
leads to dose- and time-dependent neuron loss in association with 
gliosis, cerebral atrophy, and rare TDP-43 aggregates.
Cytoplasmic TDP-43 expression leads to progressive neuron loss in tTA/
TDP-ΔNLS mice. To evaluate the effects of TDP-43-ΔNLS overex-
pression in the cytoplasm, we assessed tTA/TDP-ΔNLS4 mice to 
determine whether neuron loss also occurred with time. Although 
DG neurodegeneration was variable 1 week after Dox removal, 
mice sacrificed later displayed increasing levels of neurodegenera-
tion (Figure 3, A–D). Quantitative analyses indicated more acute 
neuron loss in ΔNLS4 mice such that approximately 50% of the 
DG neurons were gone at 1 month after induction (Figure 3K). 
Consistent with the prominent degeneration of neurons in both 
tTA/TDP-ΔNLS lines, IHC for GFAP and Iba-1 demonstrated 
massive gliosis in cortical and hippocampal regions, while areas 
of low transgene expression (i.e., cerebellum, spinal cord) with 
no evidence of neuron loss showed no gliosis (Supplemental Fig-
ure 3B and data not shown). Selective vulnerability of particular 
brain regions such as the DG and the deep neocortical layers was 
observed, while other regions with similar transgene expression 
such as the hippocampal CA1 subfield and the olfactory bulb were 
relatively resistant to neurodegeneration (Supplemental Figure 4). 
Further, IHC studies demonstrated cytoplasmic localization of 
hTDP-43-ΔNLS in most neurons (70%–90%) of the hippocampus 
(Figure 3, E–J) and cortex (Supplemental Figure 3A), although 
some hTDP-43 nuclear staining was observed (see also Supple-
mental Figure 7A). To better quantify the distribution of exoge-
nous hTDP-43-ΔNLS protein, cortical extracts were separated into 
enriched nuclear and cytoplasmic fractions and immunoblotted 
for hTDP-43 and h+mTDP-43 (Figure 3L). Control monogenic 
tTA mice showed no exogenous hTDP-43 protein in either frac-
tion, whereas endogenous mTDP-43 was predominantly nucle-
ar. In contrast, in tTA/TDP-ΔNLS mice, exogenous protein was 
found in both nuclear and cytoplasmic fractions, indicating that 
the ΔNLS mutations were effective in misdirecting TDP-43 to the 
cytoplasm in concordance with the above IHC results. These find-
Figure 4
TDP-43 aggregates are phosphorylated and 
ubiquitinated in tTA/TDP-ΔNLS mice. (A–H) 
TDP-43 aggregates in cortex and hippocam-
pus of tTA/TDP-ΔNLS mice. IHC of cortex from 
tTA/TDP-ΔNLS4 (A) and tTA/TDP-ΔNLS19 
mice (B) at 1 month off Dox with p409/410 
TDP-43 antibody shows relatively few aggre-
gates in tTA/TDP-ΔNLS4 mice and higher 
number of inclusions in tTA/TDP-ΔNLS19 
mice. Inclusions in the DG (C–E) and cortex 
(F–H) of tTA/TDP-ΔNLS19 mice 1 week off 
DOX were immunopositive for p409/410 TDP-
43 (C and F), p403/404 TDP-43 (D and G), 
and ubiquitin (Ub) (E and H) antibodies. (I–N) 
Colocalization of pathologic epitopes in TDP-
43 aggregates. IF staining with antibodies to 
ubiquitin (green) and p409/410 TDP-43 (red) 
demonstrated extensive colocalization within 
pathological cytoplasmic aggregates (arrows) 
in cortex (I–N) from tTA/TDP-ΔNLS19 mice 
1 week off Dox. Scale bars: 50 μm (A and B); 
20 μm (C–E).
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ings demonstrated that overexpression of a ΔNLS mutant form of 
TDP-43 leads to cytoplasmic and nuclear TDP-43, neuron death, 
and gliosis in the hippocampus and cortex. The somewhat faster 
rate of neurodegeneration in tTA/TDP-ΔNLS mice relative to tTA/
TDP-WT mice appeared to be due to the more widespread, uni-
form expression pattern of TDP-43-ΔNLS protein compared with 
the mosaic expression pattern of hTDP-43-WT.
Hyperphosphorylated and ubiquitinated hTDP-43 aggregates in tTA/
TDP-ΔNLS mice. To investigate whether the overexpression of 
hTDP-43-ΔNLS leads to the accumulation of hyperphosphorylat-
ed, ubiquitinated cytoplasmic aggregates similar to human TDP-
43 proteinopathies (2, 24, 25), IHC was performed using antibod-
ies to phosphorylated epitopes p409/410 and p403/404 of TDP-43 
and ubiquitin as markers of pathologically modified TDP-43. 
Analysis of tTA/TDP-ΔNLS4 mice showed very rare TDP-43 aggre-
gates in less than 1% of cortical neurons, which peaked at 1 month 
off Dox (Figure 4A). Aggregates in other brain regions, such as 
the hippocampus and striatum, also were rare to absent (<0.1% of 
neurons). In contrast, higher-expressing tTA/TDP-ΔNLS19 mice 
exhibited slightly more cytoplasmic aggregates in hippocampus 
(Figure 4, C–E) and cortex (Figure 4, B and F–H). These aggregates 
peaked at 1 week and 1 month off Dox for the hippocampus and 
neocortex, respectively, and decreased thereafter. No pathologi-
cal aggregates were detected in nTg and single tetO-TDP-ΔNLS 
mice, or in cerebellum or brainstem of ΔNLS4 and ΔNLS19 mice 
(data not shown). Double-label immunofluorescence (IF) (Figure 
4, I–N) using antibodies to p409/410 and ubiquitin demonstrated 
extensive colocalization in cytoplasmic TDP-43 aggregates. Hence, 
cytoplasmic expression of hTDP-43 triggers variable accumulation 
of hTDP-43-ΔNLS aggregates that are hyperphosphorylated and 
ubiquitinated. However, the paucity of aggregates in tTA/TDP43-
ΔNLS4 mice indicated that cytoplasmic inclusions were not 
required for neuron death.
Clasping motoric phenotype and CST degeneration in tTA/TDP-ΔNLS 
mice. Previous studies showed that the overexpression of hTDP-43-
WT and mutants associated with ALS in spinal cord motor neu-
Figure 5
Motor dysfunction and CST degeneration in tTA/TDP mice. (A) Prevalence of abnormal limb-clasping motor phenotype. tTA/TDP-ΔNLS4 mice 
showed an early and time-dependent increase in abnormal clasping behavior, with all mice showing motor impairment within 3 weeks off Dox. 
A lower proportion of tTA/hTDP-WT mice (aggregate data for all WT lines) showed motor impairment only after several months off Dox. This 
clasping behavior corresponds to spasticity that occurs in PLS and ALS. (B) Axonal loss and gliosis of the CST after 1 month off Dox. IHC 
analysis of the cervical spinal cord using antibodies against phosphorylated NF-H (top row: RMO217) and phosphorylated NF-H+M (second 
row: TA51) showed loss of axons in the CST (ventral portion of the dorsal columns, top rows). Higher-power view of this region stained with a 
rabbit anti-NFL antibody in nTg mice showed numerous puncta corresponding to axons in cross-section, which is reduced in tTA/TDP-ΔNLS4 
mice (third row). GFAP IHC demonstrated moderate gliosis in tTA-TDP-WT (both WT5 and WT12) and severe gliosis in tTA/hTDP-ΔNLS4 mice. 
H&E sections of the proximal and distal forelimb and hind limb showed no evidence of atrophy or grouping. Representative sections of biceps 
are shown. Scale bars: 100 μm (top 2 rows); 10 μm (third row); 50 μm (bottom 2 rows).
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rons led to motor impairments (16–20). Since the Camk2a pro-
moter does not direct hTDP-43 expression in spinal cord motor 
neurons (see Figure 1), we asked whether hTDP-43-ΔNLS expres-
sion in motor cortex is sufficient to cause motor impairments. 
Abnormal “clasping” is a measure of spastic motor impairment 
(26–28), and the tTA/TDP-ΔNLS mice displayed abnormal limb 
clasping as early as 1 week after induction and throughout their 
life spans until sacrifice at 6 months after induction (Figure 5A). 
In contrast, the tTA/TDP-WT mice showed less robust and more 
variable clasping, which was detected only after approximately 1–3 
months after induction (Figure 5A). No clasping phenotype was 
observed in nTg or single Tg littermates.
To determine whether upper motor neuron pathology is respon-
sible for this motoric phenotype, sections of brain, spinal cord, 
and skeletal muscle were examined for evidence of degeneration. 
Gliosis was noted at all levels of the CST in tTA/TDP-ΔNLS mice, 
Figure 6
Downregulation of endogenous nuclear mTDP-43 in neurons overexpressing cytoplasmic or nuclear hTDP-43. (A–I) hTDP-43 downregulates 
mTDP-43. IF for hTDP-43 (green) or mTDP-43 (red) in DG of tTA/TDP-WT12 (A–C) or tTA/TDP-ΔNLS4 (D–F) 1 month off Dox showed neurons 
expressing hTDP-43 with loss of mTDP-43 staining (insets: higher magnification). (G–I) IF for hTDP-43 (red) or mTDP-43 (green) of cortex from 
tTA/TDP-WT12 mice 1 month off Dox showed loss of mTDP-43 expression in neurons expressing hTDP-43 (arrows). (J) Intranuclear mTDP-43 
aggregates. IHC of tTA/TDP-ΔNLS19 cortex for mTDP-43 showed rare intranuclear aggregates (insets: higher magnification of boxed regions). 
Note the absence of mTDP-43 in neurons with aggregates (*) compared with a cell with reduced (**) or normal (***) mTDP-43 expression. Scale 
bars: 200 μm (A–F); 20 μm (G–I); 50 μm (J). (K) Reduced mTDP-43 protein in tTA/TDP mice. Immunoblot for hTDP-43, mTDP-43, and h+mTDP-
43 of cortical RIPA extracts from tTA/TDP-WT12 or tTA/TDP-ΔNLS4 at various times off Dox showed increased hTDP-43 and reduced mTDP-43 
protein relative to nTg (–/–) and tetO-TDP monogenic (+/–) mice. GAPDH is a loading control. (L) Quantification of immunostained sections of 
DG from tTA/TDP-WT12, tTA/TDP-ΔNLS4 mice, and control nTg and monogenic (tTA only or tetO-TDP only) mice (n = 29). The percentage 
of neurons with inclusions (green, p409/410 stained sections), percentage of neurons with reduced mTDP-43 expression (red, anti-mTDP43 
stained sections) and percentage of neuronal degeneration (blue, H&E sections as in Figures 2 and 3) are shown as mean ± SEM versus time 
off Dox (t = 0 represents control mice).
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including the striatum, cerebral peduncles, medullary pyramids, 
and cervical spinal cord (Supplemental Figure 5). Using antibod-
ies to phosphorylated and phosphorylation-independent neuro-
filament (NF) subunits as axonal markers, we observed select loss 
of CST axons in cervical spinal cord associated with gliosis (Fig-
ure 5B). Lower motor neuron loss was not observed, consistent 
with the absence of gliosis of the spinal cord ventral horn, and the 
absence of grouped atrophy or other abnormalities of the proximal 
Figure 7
Analysis of global mRNA expression. (A) Principal component (PC) analysis revealed a distinct global gene expression signature for tTA/TDP-
ΔNLS (tTA/TDP-ΔNLS4, blue, n = 5), while other groups (nTg n = 8, tTA/TDP-WT n = 4, and monogenic ΔNLS n = 4) were relatively admixed. 
Data shown as PC1 versus PC2 for each individual mouse. (B) Hierarchical cluster analysis of the genes differentially expressed between tTA/
TDP-ΔNLS and nTg mice (FDR < 0.05, with absolute value of FC > 2, shown here, n = 197 genes) corroborated PC analysis. Genes dysregulated 
in tTA/TDP-ΔNLS mice were evenly split between those downregulated (blue) and upregulated (red). Columns on heat map correspond to indi-
vidual animals designated as follows: tTA/TDP-ΔNLS (blue), nTg (green), tTA/TDP-WT (purple), and monogenic ΔNLS (red). Rows correspond to 
individual probe sets, with blue indicating lower, gray indicating intermediate, and red indicating higher expression. (C) Biological pathway analy-
sis of genes dysregulated in tTA/TDP-ΔNLS mice revealed many enriched pathways. The top 5 enrichment scores (negative log10 χ2 P value) 
are shown (higher score indicates greater enrichment). (D) Within the second-most-enriched pathway (macromolecular complex assembly, blue 
bar in C), most of the genes were involved in DNA-protein complex assembly. (E) Microarray and qRT-PCR results showed good concordance 
(r2 of 0.7959, and no discordant directions of change), as shown by plotting log2 FC values for microarray data (x axis) versus qRT-PCR results 
(y axis). The 6 genes that differed significantly between tTA/TDP-ΔNLS and nTg littermates (red squares) and 8 genes that did not differ signifi-
cantly between groups (black circles) are shown (see Table 2). A negative value denotes lower expression in the tTA/TDP-ΔNLS mice.
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and distal forelimb and hind limb striated muscles (Figure 5B). 
Thus, our findings support that degeneration of motor neurons 
in the cortex is sufficient to elicit a motoric phenotype reminiscent 
of both FTLD-TDP and PLS due to the selective involvement of 
upper but not lower motor neurons.
Nuclear or cytoplasmic overexpression of hTDP-43 leads to downregula-
tion of endogenous mTDP-43. Since the profound neurodegeneration 
in tTA/TDP-ΔNLS mice could not be accounted for by rare cyto-
plasmic TDP-43 inclusions and since previous studies have shown 
that hTDP-43-WT or hTDP-43-ΔNLS expression reduces endog-
enous mTDP-43 levels in cultured nonneuronal cells (11), we 
asked whether overexpression of hTDP-43 decreases endogenous 
mTDP-43. To this end, we developed what we believe is a novel 
mouse-specific TDP-43 polyclonal antibody raised to a synthetic 
peptide corresponding to residues 203–219 of mTDP-43 (only 
58% sequence identity with hTDP-43). Triple-affinity purification 
of the polyclonal antisera showed that it reacted specifically with 
mTDP-43 and not hTDP-43 by immunoblot and by IHC analyses 
(Supplemental Figure 6). Double-label IF using antibodies specific 
for hTDP-43 and mTDP-43 showed the absence or a reduction of 
endogenous mTDP-43 in neurons that expressed hTDP-43 in both 
tTA/TDP-WT (Figure 6, A–C) and tTA/TDP-ΔNLS (Figure 6, D–F) 
mice. Indeed, higher-power images showed that neurons expressing 
exogenous hTDP-43 protein exhibited reduced immunostaining 
of endogenous mTDP-43 (Figure 6, G–I). Interestingly, since tTA/
TDP-ΔNLS mice show more uniform transgene expression, greater 
numbers of DG neurons were devoid of mTDP-43 expression, in 
contrast with the mosaic expression of hTDP-43-WT and the con-
comitant mosaic reduction of mTDP-43 in tTA/TDP-WT mice 
(compare Figure 6, A–C with D–F). Notably, neurodegeneration 
was only seen in regions in which there was a reduction of nuclear 
mTDP-43 staining. Regions with low or no transgene expression 
or neurodegeneration, such as the ventral motor neuron pool in 
spinal cord, showed no change in endogenous nuclear mTDP-43 
staining (data not shown). Interestingly, very rare cells with mTDP-
43 nuclear inclusions were identified (Figure 6J). Significantly, we 
also did not observe sequestration of endogenous mTDP-43 into 
hTDP-43 inclusions in our hTDP-43 Tg mice.
The reduction of endogenous mTDP-43 secondary to exogenous 
hTDP-43 expression was confirmed by immunoblotting. Endog-
enous mTDP-43 protein was decreased in tTA/TDP-WT12 mice at 
6 months off Dox, whereas mTDP-43 protein was reduced as early 
as 1 month off Dox in tTA/hTDP-ΔNLS4 mice (Figure 6K). The 
delayed biochemical detection of mTDP-43 reduction was consis-
tent with the slower onset and mosaic expression pattern of tTA/
TDP-WT12 mice. To confirm that endogenous nuclear TDP-43 
protein was reduced in Tg mice, immunoblotting of nuclear versus 
cytoplasmic enriched fractions was performed, which showed that 
in control mice, endogenous mTDP-43 is detected only in nuclear 
enriched fractions and that nuclear mTDP-43 protein levels are 
reduced in tTA/TDP-ΔNLS4 mice (Figure 3L). Given the neuronal 
specificity of the Camk2a promoter, the decrease in mTDP-43 pro-
tein levels in whole cortical lysates is indicative of a marked reduc-
tion of mTDP-43 protein in affected cells.
To examine the relationship among neurodegeneration, TDP-
43 aggregates, and the downregulation of endogenous mTDP-43, 
quantification of percentage of neuron loss, percentage of neurons 
with TDP-43 aggregates, and percentage neurons with reduced 
mTDP-43 protein was performed (Figure 6L). TDP-43 aggregates 
in DG were extremely rare at all time points and therefore bear 
no relationship with neuron loss. In contrast, the reduction in 
mTDP-43 protein appeared to correlate with the extent of neuro-
degeneration. Significantly, more rapid degeneration in tTA/TDP-
ΔNLS mice compared with tTA/TDP-WT mice was matched with 
more uniform and rapid loss of mTDP-43 protein. Moreover, the 
number of neurons with loss of mTDP-43 protein decreased rela-
tive to the number of unaffected neurons as a function of time off 
Dox, suggesting that neurons with reduced mTDP-43 protein are 
selectively vulnerable. Hence, these data indicate that overexpres-
sion of hTDP-43 leads to a downregulation of endogenous nuclear 
mTDP-43 expression, which correlates with the rate and extent of 
neurodegeneration, suggesting that dysregulation of endogenous 
TDP-43 activity may be linked to neuron death.
tTA/TDP-ΔNLS mice demonstrate substantial alterations in gene expres-
sion, particularly affecting chromatin assembly pathways. Thus far, our 
data suggest that endogenous mTDP-43 expression is strongly 
affected by exogenous hTDP-43 expression. Presumably, this 
tight regulation is required for the normal physiologic functions 
of endogenous TDP-43. To better understand the consequences 
of these observed changes, in particular the genome-wide effects 
of expressing hTDP-43-ΔNLS and perturbing mTDP-43, we used 
microarrays to evaluate global gene expression in the cortices of 
tTA/TDP-ΔNLS and tTA/TDP-WT animals relative to single Tg 
mice and nTg littermates. The inducible system allows analysis of 
relatively rapid changes in gene expression to avoid unrelated devel-
opmental effects and before secondary reactive changes due to neu-
rodegeneration confound our analysis. Mice were studied at 2 weeks 
off Dox, a time point when tTA/TDP-ΔNLS mice showed uniform 
hTDP-43 expression and widespread reduction in mTDP-43, but 
prior to onset of significant gliosis and massive cell loss. It is worth 
noting that the widespread hTDP-43 expression observed in tTA/
TDP-ΔNLS mice at this 2-week time point stands in contrast with 
tTA/TDP-WT mice, which showed mosaic hTDP-43 expression in 
less than 10% of neurons (Supplemental Figure 7A). The differing 
levels of transgene expression in the tTA/TDP-ΔNLS and tTA/TDP-
WT mice were corroborated by both hTDP-43 mRNA (Supplemen-
tal Figure 7B) and protein levels (Supplemental Figure 7C), which 
showed robust hTDP-43 expression in tTA/TDP-ΔNLS mice relative 
to tTA/TDP-WT mice at early time points after Dox removal.
In cortical samples from tTA/TDP-ΔNLS4 (at 2 weeks when there 
is minimal confounding changes due to gliosis and neuron loss), 
Table 1
Top 10 genes in the DNA-protein complex assembly pathway
Gene name P value FC
Nucleosome assembly protein 1-like 1 5.78 × 10–11 –1.2504
Nucleosome assembly protein 1-like 1/ 2.61 × 10–09 –1.2624
 predicted gene 4204
Histone cluster 1, H2bp 1.13 × 10–08 1.8277
Histone cluster 1, H4a/H4b/H4c 1.41 × 10–08 1.8690
Prion protein 1.41 × 10–08 1.2641
Histone cluster 1, H3d 1.55 × 10–07 2.2811
Nucleosome assembly protein 1-like 2 1.84 × 10–07 –1.4639
Olfactomedin 1 4.64 × 10–07 –1.1636
Histone cluster 1, H4h 5.09 × 10–07 2.3303
Nucleosome assembly protein 1-like 1 1.18 × 10–06 –1.2576
Genes were ordered by smallest nominal P value comparing tTA/TDP-
ΔNLS mice relative to nTg littermates.
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all the tTA/TDP-ΔNLS animals (n = 5), regardless of sex, showed 
a dramatically different global gene expression profile compared 
with the other mouse lines (Figure 7, A and B). In all, more than 
4,700 genes were differentially expressed between tTA/TDP-ΔNLS 
and nTg mice (false discovery rate [FDR] < 0.05), with 197 show-
ing fold change (FC) differences greater than 2. Differentially 
expressed genes were evenly distributed between those increased 
versus decreased in tTA/TDP-ΔNLS mice (Figure 7B), making it 
unlikely that neuron loss alone could account for these findings. 
Biological pathway analysis of differentially expressed genes fur-
ther revealed a number of dysregulated pathways (Figure 7C), with 
the relatively nonspecific category “response to stimulus” show-
ing the greatest enrichment in dysregulated genes, followed by the 
category “macromolecular complex organization,” with a highly 
significant enrichment score of 8.3, corresponding to a P value of 
less than 10–8. Within this category, genes involved in chromatin 
assembly accounted for the significant enrichment of the entire 
category (Figure 7D), with 4 of the top 10 genes in this category 
coding for histones (Table 1). Remarkably, all 4 histone genes were 
upregulated in the tTA/TDP-ΔNLS mice.
In contrast with the tTA/TDP-ΔNLS animals, the tTA/TDP-WT 
mice (n = 4), which express much lower levels of transgene and 
have correspondingly less repression of endogenous mTDP-43, 
showed more modest changes in global gene expression (Figure 
7A). While these animals did separate from nTg mice, their global 
gene expression signature appeared to be intermediate between 
the nTg and tTA/TDP-ΔNLS mice (Figure 7, A and B).
To validate our microarray findings as well as interrogate the 
expression of genes previously reported to be affected by TDP-43, 
we performed quantitative RT-PCR (qRT-PCR) on select genes. As 
shown in Figure 7E, microarray and qRT-PCR results were concor-
dant (r2 of 0.7959 across 14 genes tested on both platforms). Of 
note, while some genes previously reported to be affected by TDP-43 
(e.g., Nefl) were dysregulated in both our microarray and qRT-PCR 
experiments, this was not true for other genes reported to be tran-
scriptionally affected by TDP-43 (e.g., Hdac6 and Cdk6) (29–31). In 
addition, the mouse Tardbp gene itself is downregulated by log2 FC 
of –0.55 (32% reduction) by qRT-
PCR in tTA/TDP-ΔNLS mice rela-
tive to nTg littermates (Table 2). 
This finding is concordant with 
our IF and immunoblot studies 
demonstrating that endogenous 
mTDP-43 is downregulated in 
the presence of exogenous hTDP-
43 and implies that at least part 
of this regulatory effect occurs 
at the mRNA level. Significantly, 
we noted that mRNA markers of 
astrocytes (Gfap), microglia (Cd34), 
and neurons (Nefm) did not differ 
substantially between the tTA/
TDP-ΔNLS mice and their nTg lit-
termates, thereby indicating that 
gliosis, microglial infiltration, and 
neuron loss were not responsible 
for the gene expression changes 
seen here.
Taken together, these data indi-
cate that tTA/TDP-ΔNLS mice 
show significantly altered global gene expression affecting spe-
cific pathways such as chromatin assembly. Although tTA/TDP-
WT mice showed a somewhat intermediate profile, their pattern 
of gene expression was closer to that of nTg mice, presumably due 
to their mosaic hTDP-43 expression pattern affecting only a small 
subset of neurons at the time point studied. Regardless, specific 
biological pathways, in particular those involved in chromatin 
assembly, were linked to the dysregulation of endogenous TDP-
43 and downstream neurodegeneration.
Discussion
TDP-43 is a multifunctional DNA- and RNA-binding protein 
expressed mainly in the nucleus of nearly all cells, but abnormal 
forms of TDP-43 aggregate mostly as cytoplasmic inclusions in 
FTLD-TDP and ALS. It is unclear whether the mechanisms of dis-
ease pathogenesis are due to loss of normal TDP-43 function or a 
gain of toxic function linked to aggregate formation or accumula-
tion of TDP-43 CTFs. Furthermore, the relative roles of mislocaliza-
tion, abnormal expression, abnormal downregulation, or aggrega-
tion of TDP-43 in causing neurotoxicity are not known. To address 
these questions, we generated Tg mice selectively expressing hTDP-
43-ΔNLS in forebrain neurons and compared them with hTDP-43-
WT–expressing Tg mice using the Camk2a tet-O inducible system. 
Remarkably, we found that endogenous mTDP-43 is tightly regu-
lated and that expression of hTDP-43-ΔNLS or TDP-43-WT leads 
to a reduction of nuclear mTDP-43 in vulnerable neurons with 
associated neuron death, thereby implicating the dysregulation of 
nuclear TDP-43 expression and the loss of nuclear TDP-43 func-
tions in the pathogenesis of TDP-43 proteinopathies.
The regional expression pattern of hTDP-43 in our Tg mouse 
models followed that of Camk2a promoter and was accompanied 
by the selective degeneration of hippocampal DG neurons, neocor-
tical neurons (including the axons of upper motor neurons), and 
the CST emanating from upper motor neurons with sparing of 
spinal cord motor neurons. Thus, these Tg mice, especially tTA/
TDP-ΔNLS mice, recapitulate key aspects of FTLD-TDP and PLS 
including (a) progressive and targeted neurodegeneration, (b) dys-
Table 2
qRT-PCR verification of microarray results
 P value log2 FC
Gene name Symbol Array qRT-PCR Array qRT-PCR
Sperm associated antigen 5 Spag5 0.00000 0.00002 –2.10 –2.27
NF, light polypeptide Nefl 0.00023 0.00008 –0.35 –1.05
TAR DNA–binding protein 43 Tardbp 0.00000 0.00001 –0.98 –0.55
Heterogeneous ribonucleoprotein A3 Hnrnpa3 0.00000 0.00646 –0.64 –0.30
Histone cluster 1, H3d Hist1h3d 0.00000 0.00489 1.19 0.21
Antisilencing function 1 homolog A Asf1a 0.00000 0.00002 0.83 0.66
Cyclin-dependent kinase 6 Cdk6 0.34964 0.00895 –0.06 –0.32
Microtubule-associated protein 2 Mtap2 0.82589 0.03381 0.04 –0.28
Histone deacetylase 6 Hdac6 0.60055 0.26069 –0.04 –0.09
CD34 antigen Cd34 0.72897 0.47809 –0.04 0.01
Glial fibrillary acid protein Gfap 0.18572 0.37695 0.32 0.04
NF, medium polypeptide Nefm 0.69349 0.34692 –0.02 0.06
Granulin Grn 0.53551 0.06419 0.09 0.22
Glutamate receptor, ionotropic,  Grin1 0.07654 0.00003 0.95 0.69
 NMDA1 (zeta 1)
Gene expression assessed by microarray and qRT-PCR for 14 selected genes. P values and log2 FC relative 
to nTg mice are shown, with negative FC values denoting lower expression in the tTA/TDP-ΔNLS mice.
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regulation and loss of endogenous TDP-43, and (c) presence, albeit 
rare, of phosphorylated and ubiquitinated TDP-43 inclusions in 
affected neurons. Moreover, the observed spastic motor pheno-
type is likely due to selective degeneration of axons in the CST that 
emanate from upper motor neurons without TDP-43 pathology in 
or degeneration of spinal cord motor neurons in tTA/TDP-ΔNLS 
mice. Thus, our results suggest that it is possible to model a PLS-
like phenotype in Tg mice where TDP-43 dysfunction affects motor 
cortex without subsequent lower motor neuron degeneration.
Both tTA/TDP-ΔNLS and tTA/TDP-WT mice showed time-
dependent neurodegeneration. However, only the highest express-
ing tTA/TDP-ΔNLS19 mice showed significant, but very small 
numbers of TDP-43 aggregates, while tTA/TDP-ΔNLS4 and all tTA/
TDP-WT lines showed vanishingly few TDP-43 aggregates, suggest-
ing that inclusions may not be necessary for neurodegeneration. 
Instead, neuron loss may result from perturbations of endogenous 
mTDP-43. Supporting such an argument are studies demonstrat-
ing that endogenous TDP-43 expression is tightly regulated and is 
critical for survival. For example, knockout of Tardbp in mice led to 
embryonic lethality (12–15), heterozygous knockout mice develop 
motor impairments with age (12), and conditional knockout mice 
exhibit rapid postnatal lethality (15). Further, downregulation of 
TDP-43 in differentiated Neuro-2a cells inhibits neurite outgrowth 
and induces cell death (32). These studies indicate that perturba-
tion of normal TDP-43 function is detrimental.
Although WT or mutant human or mouse TDP-43 expression 
in Drosophila or Tg mice has been shown to cause neurotoxicity, 
the exact cause of neurodegeneration in these models is unknown 
(16–20, 33). Our mice are similar to previously reported Tg mice 
in that we observe selective vulnerability of neuronal populations 
including upper motor neurons, a motor phenotype, and the vari-
able presence of TDP-43 aggregates (16–20). These previously 
reported Tg mouse models implicate pathological aggregates, high 
levels of insoluble TDP-43, and measurable levels of TDP-43 CTFs 
as likely causes of neurodegeneration. However, the low levels (<10%) 
of insoluble TDP-43 and the absence of CTFs with only rare TDP-
43 inclusions in our tTA/TDP-ΔNLS and tTA/TDP-WT mice make 
it unlikely that insoluble hTDP-43 aggregates are directly respon-
sible for neuron loss in our Tg mice. Indeed, varying levels of deter-
gent-soluble CTFs have been detected in brain lysates of other Tg 
lines (16–20). However, we observed a very similar neurodegenera-
tion phenotype compared with these other models, indicating that 
CTFs are not a requisite for neurodegeneration. Although we cannot 
exclude a toxic gain of function due to overexpressed hTDP-43, our 
demonstration that hTDP-43 expression leads to downregulation of 
endogenous mTDP-43 mRNA and protein in neurons, which cor-
relates with neuron death, suggests that the dysregulation of nor-
mal mTDP-43 expression and thus disruption of normal mTDP-43 
function may be a major contributor to neurodegeneration.
Notably, we demonstrated direct “replacement” of mTDP-43 by 
exogenous hTDP-43 in both the tTA/TDP-WT and tTA/TDP-ΔNLS 
models by generating what we believe is a novel antibody specific to 
endogenous mTDP-43. The availability of species-specific antibod-
ies to endogenous mTDP-43 and exogenous hTDP-43 allows us to 
conduct quantitative IHC in our Tg mice to determine the tem-
poral relation of mTDP-43 and hTDP-43 neuronal expression at 
various time points off Dox in our Tg mice. We found that neuron 
death was linked to loss of mTDP-43 protein and not to the num-
ber of TDP-43 aggregates. Thus, the perturbation of endogenous 
mTDP-43 by the overexpression of hTDP-43 appears sufficient to 
cause neuron loss, perhaps due to the inability of hTDP-43 ortho-
log to replace the function of mTDP-43 or because perturbation of 
the tight regulation of TDP-43 leads to aberrant TDP-43 function, 
thereby resulting in neurodegeneration. Other Tg models have 
shown that neurons bearing TDP-43 inclusions exhibit absence of 
nuclear TDP-43 protein by IHC, similar to that seen in human dis-
ease tissue (16–18). Furthermore, we and others have shown that 
exogenous TDP-43 protein expression downregulates endogenous 
TDP-43 expression in cell or tissue homogenates (11, 20). Our cur-
rent results are unique in that we link “nuclear clearing” and the 
dysregulation of endogenous TDP-43 expression and show that the 
regulation of TDP-43 expression occurs on the cellular level in neu-
rons expressing hTDP-43 even in the absence of TDP-43 inclusions. 
This was the major correlate to neuron death, suggesting that dys-
regulation of TDP-43 expression is linked to neurodegeneration.
Since the pathways by which TDP-43 dysregulation leads to neu-
rodegeneration are not entirely known, it is difficult to be certain 
that hTDP-43 overexpression is unable to compensate for the loss 
of mTDP-43 expression. However, we note that the stabilization of 
Nefl mRNA is the only neuron-specific effect of TDP-43 protein that 
is currently known (31). Consistent with a loss of TDP-43 function 
in neurons, we observed a specific reduction in Nefl expression in 
Tg mice, while expression of Nefm and Nefh were unchanged. More-
over, a recent study overexpressing WT mTDP-43 in Tg mice using 
a Camk2a promoter (16) showed similar neurodegeneration as the 
overexpression of hTDP-43. Therefore, an important determinant 
of neurotoxicity may be the dysregulation of TDP-43 expression.
The mechanism whereby both exogenous hTDP-43-ΔNLS and 
hTDP-43-WT results in a reduction in mTDP-43 expression is 
not known. However, since we observed high levels of the TDP-
43-ΔNLS protein in the nucleus, the most parsimonious explana-
tion for neurodegeneration in our Tg mice is that elevated levels of 
nuclear hTDP-43 protein result in downregulation of endogenous 
mTDP-43 mRNA and nuclear mTDP-43 protein levels. However, 
since TDP-43-ΔNLS protein is also localized to the cytoplasm in 
our mice, we cannot entirely exclude the possibility that cytoplas-
mic TDP-43 plays a role in the reduction of endogenous TDP-43 or 
has a direct neurotoxic effect. Nonetheless, since downregulation 
of endogenous nuclear mTDP-43 was observed in both hTDP-43-
WT and hTDP-43-ΔNLS mice, it is plausible that perturbation of 
nuclear TDP-43 protein levels leads to dysregulation of endoge-
nous mTDP-43 expression, which culminates in neuron death.
Our tTA/TDP-ΔNLS mice provide unique opportunities to study 
global changes in gene expression mediated by TDP-43. This is 
because of the synchronized inducible overexpression of TDP-43-
ΔNLS in approximately 80% of the neurons and the identification 
of a window of opportunity at 2 weeks off Dox where transgene 
was expressed and endogenous mTDP-43 protein was reduced, 
and secondary reactive changes such as gliosis in response to neu-
rodegeneration were at a minimum. Such profound changes in 
gene expression were not detected in tTA/TDP-WT mice, likely due 
to the low percentage of neurons (~10%) expressing transgene and 
nearly normal endogenous mTDP-43 expression in tTA/TDP-WT 
mice at 2 weeks off Dox. The reason for nonsynchronized trans-
gene expression in tTA/TDP-WT mice is not known, but 3 of the 4 
lines of tTA/TDP-WT mice reported here showed this phenotype. 
Thus, we infer that the profound changes in global gene expres-
sion observed in tTA/TDP-ΔNLS but not in the tTA/TDP-WT 
mice reflect the uniform loss of endogenous mTDP-43. Although 
these findings clearly require further studies of TDP-43–knockout 
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or –knockdown models, our data prompt us to hypothesize that 
these changes in gene expression result from a loss of function of 
normal nuclear TDP-43. In summary, the behavioral, biochemi-
cal, IHC, and molecular analyses of these inducible hTDP-43 Tg 
mice advance our understanding of the biology of TDP-43, in par-
ticular, with regards to the tight regulation of TDP-43 expression, 
thereby underscoring the integral role of TDP-43 expression in 
gene regulation and neurodegeneration pathways.
Methods
Generation of hTDP-43-WT and -ΔNLS transgenic mice. hTDP-43 Tg lines were 
generated by injection of linearized moPrP-tetP vector containing hTDP-
43-WT and hTDP-43-ΔNLS cDNA (11) into pronucleus of fertilized eggs 
from C57BL/6J × C3HeJ F1 matings (34). Monogenic tetO-TDP-WT and 
tetO-TDP-ΔNLS mice were bred to Camk2a-tTA mice (Jackson Laboratory) 
generating nTg, tTA monogenic, single tetO-TDP-43 Tg mice, and big-
enic mice expressing hTDP-43-WT or hTDP-43-ΔNLS (Figure 1A). Breed-
ing mice and pups were fed chow containing 200 mg/kg Dox (Dox Diet, 
S3888; Bio-Serv). Mice were switched to standard chow (Lab Diet 5053, 
Test Diet; PMI International) to induce hTDP-43 expression (Figure 1B). 
Genotyping from tail DNA (35) was performed using the following prim-
ers: TDP-forward (TTGGTAATAGCAGAGGGGGTGGAG), MoPrP-reverse 
(TCCCCCAGCCTAGACCACGAGAAT), Camk2a -tTA-forward (CGCTGT-
GGGGCATTTTACTTTAG), and Camk2a-tTA-reverse (CATGTCCAGATC-
GAAATCGTC). All procedures were performed in accordance with the NIH 
Guide for the Care and Use of Experimental Animals and approved by the 
University of Pennsylvania Institutional Animal Care and Use Committee.
Antibodies. Antibodies used in this study were as follows: rabbit anti–
TDP-43 polyclonal antibody (pAb) raised to amino acids 1–260 (Protein-
tech Group), a human specific mouse mAb raised to the same TDP-43 
sequence (Proteintech), rabbit anti–phospho-Ser403/Ser404 TDP-43 
(Cosmo Bio Co.), rabbit anti-GFAP (DAKO North America), rabbit 
anti–Iba-1 (Wako Chemicals USA), rabbit anti-ubiquitin (DAKO), anti– 
α-glyceraldehyde-3-phosphate dehydrogenase (GAPDH 6C5 mouse mAb; 
Advanced ImmunoChemical Inc.), anti-NF mAbs to phosphorylated epi-
tope on high-Mr NF (pNF-H) subunit and mid- and high-Mr NF (pNF-
M+H) subunits as well as a rabbit pAb to the low NF (NF-L) subunit (36), 
affinity-purified rabbit anti–TDP-43 pAb raised to amino acids 394–414 
(h+mTDP-43; ref. 37), and rat phospho-specific mAb that recognizes TDP-
43 phosphorylated at Ser409/Ser410 (p409/410; ref. 25). 15A, an affinity-
purified pAb specific for mTDP-43, was generated by immunizing rabbits 
with a synthetic peptide corresponding to residues 203–219 of mTDP-43 
(TAEELQQFFCQYGEVVD) and was characterized by immunoblot and 
IHC (Supplemental Figure 6).
Immunohistochemistry and histological staining. Mice were perfused and tis-
sues were processed for IHC and IF as described (21). In general, the left 
hemisphere was dissected into cortex, hippocampus, cerebellum, olfactory 
bulb, and the rest of the tissue (subcortical structures, brainstem) and fro-
zen at –80°C until used for biochemical analysis. The right hemisphere and 
spinal cord sections were immersed in neutral buffered formalin (NBF) 
(Fisher Scientific) and processed for IHC (21, 35).
For unbiased estimates of hippocampal DG neuron numbers, H&E coro-
nal sections at the level of the mammillary body were used for quantitative 
analysis (n = 3–4 per group) as previously described (35). Digital photomi-
crographs were used to manually count the number of DG granule neu-
rons. For quantification of percentage of neurons with reduced mTDP-43 
and the percentage of neurons with TDP-43 aggregates, high-power pho-
tomicrographs of the DG from sections immunostained for mTDP-43 or 
p409/410 were manually counted and the percentage of viable neurons with 
reduced mTDP-43 staining or containing an inclusion was calculated.
Double-label IF was conducted as previously described (35, 37) using 
Alexa Fluor 488– and 594–conjugated secondary antibodies (Molecular 
Probes). Digital images were obtained using an Olympus BX 51 micro-
scope equipped with brightfield and fluorescence light sources using a 
DP71 digital camera (Olympus) and DP Manager software (Olympus).
SDS-PAGE and immunoblot analysis. Tissues were sequentially extracted 
first with 5 volumes (ml/g) of RIPA buffer (0.1% SDS, 1% Nonidet P-40, 0.5% 
sodium deoxycholate, 5 mM EDTA, 150 mM NaCl, 50 mM Tris-HCl, pH 
8.0) containing protease and phosphatase inhibitor cocktail. After the insol-
uble pellets were washed with RIPA buffer, they were further extracted with 
2.5 vols of urea buffer (7 M urea, 2 M thiourea, 4% CHAPS, 30 mM Tris-HCl, 
pH 8.5). 30 μg of RIPA extract or 4× equivalent vols of urea extract per lane 
were separated on a 10% Tris-glycine SDS-PAGE gel and immunoblotted as 
described (35). Digital images were acquired using a Fuji Film Intelligent 
Darkbox II (Fuji Systems). Quantification of band intensity was performed 
using Image Quant software (Molecular Dynamics). For transgene expres-
sion quantification, fold expression relative to nTg and tTA control mice 
was determined using h+mTDP-43 immunoblots within the linear range of 
band intensity after normalization to GAPDH expression.
Enriched nuclear and cytoplasmic fractions were prepared from mouse 
cortex by modified method of Guillemin et al. (38). Briefly, cortex was 
weighed, placed in hypotonic buffer containing protease inhibitors (10 mM 
HEPES-KOH, 10 mM KCl, 1.5 mM MgCl2, pH 7.4; 5:1, v/w) and homog-
enized using 8 passes of Dounce homogenizer. After incubation for 10 min-
utes at 4°C, 2.0 M sucrose (1:1, v/w) was added and the suspension further 
homogenized using 15 passes of Dounce homogenizer; it was then centri-
fuged at 1000 g for 5 minutes at 4°C. The supernatant was collected. The 
pellet was resuspended in 10 volume of hypotonic buffer containing 0.3 M 
sucrose and rehomogenized using 8 strokes of Dounce homogenizer and 
centrifuged as before. The resultant supernatant was combined with the 
first as the cytoplasmic fraction. The pellet was washed in hypotonic buf-
fer containing 0.3 M sucrose and centrifuged as before. The final enriched 
nuclear fraction was resuspended in hypotonic buffer containing 0.3 M 
sucrose. The fractions were sonicated and processed for SDS-PAGE.
Clasping phenotype. Bigenic and monogenic hTDP-43 Tg mice as well as 
age-matched control nTg mice were suspended by the tail 30 cm above an 
open cage for 30 seconds, after which they were slowly lowered toward the 
bottom of the cage. A positive response was recorded for mice that clasped 
their limbs within 5 seconds of suspension while maintaining the clasping 
posture until lowered to the cage.
Brain RNA isolation and microarray/qRT-PCR quantification. Animals from all 
groups were sacrificed and hippocampi and right cortex were immediately 
placed into QIAzol reagent (QIAGEN). Samples were homogenized by pass-
ing through a series of 3 increasingly higher-gauge needles. After homogeni-
zation, total RNA was isolated from the samples by following the protocol for 
the miRNeasy kit (QIAGEN). RNA was run on an Agilent 2100 Bioanalyzer to 
assess quality; only samples with excellent RNA quality (RNA Integrity Num-
ber [RIN] > 7) were used. For microarray experiments, RNA samples were eval-
uated on the Affymetrix Mouse Genome 430A 2.0 Array following standard 
Affymetrix protocols (GEO GSE25182). For qRT-PCR experiments, RNA was 
reverse transcribed to cDNA using SuperScript III (Invitrogen). qPCR was 
performed on the cDNA using an Applied Biosystems 7500 Fast Real-Time 
PCR system using custom-designed primers and Sybr Green. Gene expression 
values were determined by using the ΔΔCT method. Human- and mouse-spe-
cific TDP-43 primers were designed and tested with control mRNAs to assess 
lack of interspecies cross-reactivity. The genes of interest were standardized to 
the geometric mean of 2 housekeeping genes (GAPDH and β-actin). Samples 
were normalized only within a brain region to a common animal.
Microarray analysis and statistical methods. The Partek Genomics Suite was 
used to perform microarray data analysis and to generate graphics (Partek 
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GS). Affymetrix array raw fluorescence intensity measures of gene expres-
sion were normalized and quantified using robust multi-array analysis. 
To identify genes differentially expressed between groups, we employed 
ANOVA, followed by pairwise contrasts between the groups of interest. Our 
model corrected for sex. To correct for multiple hypothesis testing, we calcu-
lated FDR using the Benjamini-Hochberg method. Principal components 
analyses and hierarchical cluster analyses (Pearson’s correlation coefficient) 
were employed to evaluate patterns of global gene expression. Differentially 
expressed genes were additionally subjected to biological pathway analysis 
using the Gene Ontology database to find pathways enriched in dysregu-
lated genes; enrichment scores are the negative log10 χ2 P value.
Statistics. Statistical analyses of DG neuron counts, brain weights, and 
mTDP-43 and hTDP-43 transcripts among nTg, monogenic, and bigenic 
mouse lines were performed by 1-way ANOVA with Bonferroni’s multiple 
comparison post-hoc test (Prism 4.01; GraphPad Software). P < 0.05 was 
considered significant.
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